AmebaGone

About AmebaGone

AmebaGone is a pioneering company focused on addressing the critical issue of antimicrobial resistance by leveraging the natural predatory behavior of Dicty amoebae to target and eliminate harmful bacteria. Operating in the biotechnology sector, AmebaGone serves clients across the medical, agricultural, and industrial markets. The company’s core technology involves using Dicty amoebae to consume bacterial biofilms, which are often resistant to conventional antibiotics. This innovative approach aims to reduce the overuse of antibiotics and provide a safer, more effective method for controlling pathogenic microbes.

AmebaGone's business model is built on research and development, intellectual property, and strategic partnerships. The company holds broad patents in the US and EU, protecting its unique use of Dicty amoebae in various applications. Revenue is generated through grants, such as the NIH Phase II SBIR grant for bacterial keratitis treatment research, and through collaborations with industry partners.

The company has a strong research team with expertise in amoebic biocontrol and has been recognized in various business and innovation contests, including advancing to Phase 2 of the Wisconsin Governor's Business Plan Contest and presenting at the Ag Innovation Showcase.